Chemotherapy Monoclonal antibody Clinical stage Tyrosine kinase inhibitors (TKIs) Adenocarcinoma Maintenance chemotherapy Carcinoma CTACAE Refractory Maintenance chemotherapy Recurrence Checkpoint inhibitor performance status Tumor Minimal residual disease (MRD) Pathological stage Adjuvant treatment Cure Relapse Partial Remission Complementary therapy Palliation Grade 3, 4, or 5 Definitive treatment Complete remission Surgical margin Neoadjuvant treatment Antibody Drug Conjugate (ADCs) Active surveillance TNM staging system leukemia Cellular therapy Sarcoma ECOG performance status Chemotherapy Monoclonal antibody Clinical stage Tyrosine kinase inhibitors (TKIs) Adenocarcinoma Maintenance chemotherapy Carcinoma CTACAE Refractory Maintenance chemotherapy Recurrence Checkpoint inhibitor performance status Tumor Minimal residual disease (MRD) Pathological stage Adjuvant treatment Cure Relapse Partial Remission Complementary therapy Palliation Grade 3, 4, or 5 Definitive treatment Complete remission Surgical margin Neoadjuvant treatment Antibody Drug Conjugate (ADCs) Active surveillance TNM staging system leukemia Cellular therapy Sarcoma ECOG performance status
(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.
Chemotherapy
Monoclonal antibody
Clinical stage
Tyrosine kinase inhibitors (TKIs)
Adenocarcinoma
Maintenance chemotherapy
Carcinoma
CTACAE
Refractory
Maintenance chemotherapy
Recurrence
Checkpoint inhibitor
performance status
Tumor
Minimal residual disease (MRD)
Pathological stage
Adjuvant treatment
Cure
Relapse
Partial Remission
Complementary therapy
Palliation
Grade 3, 4, or 5
Definitive treatment
Complete remission
Surgical margin
Neoadjuvant treatment
Antibody Drug Conjugate (ADCs)
Active surveillance
TNM staging system
leukemia
Cellular therapy
Sarcoma
ECOG performance status